Profile - To The Moon

AHEAD

Posts · 28Posts · 28
Following · 0Following · 0
Followers · 0Followers · 0

- AHEADAHEAD
  ·2021-06-21
  ?
  Sorry, this post has been deleted
  195 Comment
  3
  Share
  Report
- AHEADAHEAD
  ·2021-06-20
  Nice
  A Stock Market Crash Is Coming: 5 High-Conviction Stocks to Buy Hand Over Fist When It Happens
  It might be the last thing you want to hear, but it's the truth:A stock market crash is inevitable.
  A Stock Market Crash Is Coming: 5 High-Conviction Stocks to Buy Hand Over Fist When It Happens
  254 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-06-16
  Will go up
  287 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-06-08
  Target
  240 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-06-05
  Great ariticle, would you like to share it?
  Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study
  Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Tre
  Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study
  93 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-06-04
  $Sundial Growers Inc.(SNDL)$good bet
  211 Comment
  1
  Share
  Report
- AHEADAHEAD
  ·2021-06-03
  Great ariticle, would you like to share it?
  Toplines Before US Market Open on Thursday
  Nasdaq futures lead stock dropMeme stocks fluctuated greatlyU.S. equity futures dropped with Europea
  Toplines Before US Market Open on Thursday
  124 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-06-01
  Great ariticle, would you like to share it?
  Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents
  Leverages TURBO-ZM™ Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulat
  Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents
  251 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-05-28
  Eyeing
  186 Comment
  Like
  Share
  Report
- AHEADAHEAD
  ·2021-05-12
  Great
  145 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3559365521897414","uuid":"3559365521897414","gmtCreate":1596271499458,"gmtModify":1614910979680,"name":"AHEAD","pinyin":"ahead","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":41,"tweetSize":28,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":167085858,"gmtCreate":1624239557874,"gmtModify":1703831228249,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167085858","repostId":"1121306615","repostType":4,"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165764356,"gmtCreate":1624158309675,"gmtModify":1703829732120,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165764356","repostId":"1126454279","repostType":4,"repost":{"id":"1126454279","kind":"news","pubTimestamp":1624151746,"share":"https://ttm.financial/m/news/1126454279?lang=&edition=fundamental","pubTime":"2021-06-20 09:15","market":"us","language":"en","title":"A Stock Market Crash Is Coming: 5 High-Conviction Stocks to Buy Hand Over Fist When It Happens","url":"https://stock-news.laohu8.com/highlight/detail?id=1126454279","media":"fool","summary":"It might be the last thing you want to hear, but it's the truth:A stock market crash is inevitable.\n","content":"<p>It might be the last thing you want to hear, but it's the truth:A stock market crash is inevitable.</p>\n<p>Since the March 23, 2020 bottom, investors have enjoyed a historically strong bounce-back rally -- the widely followed<b>S&amp;P 500</b>(SNPINDEX:^GSPC)has gained an impressive 90%. But both history and valuation metrics unequivocally suggest that a big drop is upcoming for the stock market.</p>\n<p><b>History is pretty clear that trouble lies ahead</b></p>\n<p>For example, there have beenone or two double-digit percentage declineswithin the three years following a bottom in each of the previous eight bear markets prior to the coronavirus crash (i.e., dating back to 1960). Although bull markets tend to last years, rebounds from a bear market are never this smooth. We're nearly 15 months past the March 2020 bear-market bottom in the S&amp;P 500 and have yet to see anything close to a double-digit correction.</p>\n<p>To add to this point, data from market analytics firm Yardeni Research shows that there have been 38 double-digit declines in the S&amp;P 500 over the past 71 years. That's a crash or correction, on average,every 1.87 years. Though the market doesn't adhere to averages, it does give a general sense of when to expect these hiccups.</p>\n<p>On a valuation basis, the S&amp;P 500's Shiller price-to-earnings (P/E) ratio is a waving red flag. The S&amp;P 500's Shiller P/E -- a measure of inflation-adjusted earnings over the previous 10 years -- almost hit 38 earlier this week. That more than doubles its 151-year average, and it's the highest level in nearly two decades. The previous four times the Shiller P/E surpassed and held above 30 during a bull market rally, the indexsubsequently declined by a minimum of 20%.</p>\n<p>Make no mistake about it -- a stock market crash is coming.</p>\n<p>Every crash or correction is an opportunity for patient investors to make money</p>\n<p>However, a crash is no reason to duck and cover. While history may signal trouble ahead, it also tells us that each and every double-digit decline has been a buying opportunity. Eventually, every big drop in the major indexes is erased by a bull-market rally. When the next crash does occur, the following five high-conviction stocks can be confidently bought hand over fist.</p>\n<p><b>CrowdStrike Holdings</b></p>\n<p>Cybersecurity is projected to beone of the safest double-digit growth trendsthis decade. No matter the size of the business or the state of the U.S./global economy, protecting enterprise and consumer data is paramount. This means cloud-based cybersecurity stock<b>CrowdStrike Holdings</b>(NASDAQ:CRWD)can thrive in any environment.</p>\n<p>CrowdStrike's successderives from its cloud-native Falcon security platform. Because it's built in the cloud and relies on artificial intelligence, it's growing smarter at identifying and responding to threats all the time. It's currently overseeing 6 trillion events on a weekly basis, and it's far more cost-effective at protecting data than on-premise solutions.</p>\n<p>We can also look to the company's income statements to see clear-cut evidence that businesses favor CrowdStrike's cybersecurity platform. It's been retaining 98% of its clients, has seen existing clients spend 23% to 47% more on a year-over-year basis for the past 12 quarters, and recently reported that 64% of its customers have purchased at least four cloud module subscriptions. Scaling with its customers is CrowdStrike's ticket to big-time cash flow expansion.</p>\n<p><b>Facebook</b></p>\n<p>Brand-name businesses can make patient investors a fortune, and social media giant<b>Facebook</b>(NASDAQ:FB)is the perfect example.</p>\n<p>When the curtain closed on March, Facebook tallied 2.85 billion monthly active users (MAU) visiting its namesake site and an additional 600 million unique MAUs visiting WhatsApp or Instagram, which it also owns. All told, this equates to44% of the global populationinteracting with its owned sites each month. There's simply no social media platform businesses can go to get their message to a broader (or potentially targeted) audience, which is why Facebook ad-pricing power is so strong.</p>\n<p>But here's the kicker: Facebookhasn't even put the pedal to the metal. Although it's on track to generate more than $100 billion in advertising revenue in 2021, nearly all of these ad sales are coming from its namesake site and Instagram. WhatsApp and Facebook Messenger, which are two of the six most-visited social sites in the world, aren't being meaningfully monetized as of yet. Further, the company's Oculus virtual reality devices are still in the early stage of their growth. Suffice it to say, Facebook offers ample upside as its other operating segments are monetized and mature.</p>\n<p><b>NextEra Energy</b></p>\n<p>Another high-conviction stock to buy hand over fist the next time a crash or steep correction strikes is electric utility stock<b>NextEra Energy</b>(NYSE:NEE).</p>\n<p>Did I put you to sleep when I said \"electric utility stock?\" Electric utilities are traditionally known for their market-topping dividend yields and persistently low growth rates. But this doesn't describe NextEra Energy. NextEra has aggressively invested in renewable energy projects and is leading the country in solar and wind capacity. As a result of these investments, its electric generation costs have declined and its compound annual growth ratehas consistently been in the high single digitsfor more than a decade. It also doesn't hurt that NextEra is front-running any potential green-energy legislation that might come out of Washington.</p>\n<p>In addition to growth rates that are well above the sector average, NextEra still benefits from the predictability of energy demand. For instance, its regulated utilities (i.e., those not powered by renewable energy) require approval from state utility commissions before price hikes can be passed along to households. This might sound like an inconvenience, but it's actually great news. It means NextEra won't be exposed to potentially volatile wholesale pricing.</p>\n<p><b>Visa</b></p>\n<p>When the next stock market crash arrives, payment processing kingpin<b>Visa</b>(NYSE:V)is a winning company to confidently buy hand over fist. It's also another brand-name company thatcan still make its shareholders a fortune.</p>\n<p>Buying into the Visa growth story is a simple numbers game. Visa grows its revenue and profits when consumers and businesses are spending more. This happens when the U.S. and global economy are expanding. Although contractions and recessions are an inevitable part of the economic cycle, they tend to be short-lived. Meanwhile, periods of economic expansion are almost always measured in years. Buying into Visa during these short-lived crashes or corrections should allow long-term investors to be handsomely rewarded by this numbers game.</p>\n<p>The other interesting thing about Visa is thatit's shunned becoming a lender. You'd think that Visa could generate big bucks from interest income and fees by lending during these long-lived periods of expansion. But lending would also expose Visa to the credit delinquencies that arise during recessions. Operating solely as a payment processor means not having to set aside cash to cover delinquencies. It's why Visa rebounds so much faster than most financial stocks following a recession.</p>\n<p><b>Amazon</b></p>\n<p>Lastly (andwho couldn't see this coming?), investors should take any discount they can get during a crash on e-commerce behemoth<b>Amazon</b>(NASDAQ:AMZN).</p>\n<p>Amazon's online marketplace has proved virtually unstoppable for well over a decade. An April 2021 report from eMarketer pegged the company's share of U.S. online sales at 40.4%. That more than quintuples its next-closest competitor and effectively solidifies Amazon as the go-to source for online shopping in the U.S.</p>\n<p>What about those pesky low retail margins, you ask? Amazon has signed up more than 200 million people globally to a Prime membership. The fees collected from Prime members help to offset some of the company's retail-based margin weakness. Prime members are extremely loyal to the Amazon ecosystem and spend far more than non-members, too.</p>\n<p>But it's Amazon's cloud infrastructure segmentthat's the superstar. Amazon Web Services (AWS) brings in around one-eighth of the company's total sales but accounts for well over half its operating income. Since cloud margins are superior to retail and advertising margins, AWS is the company's key to explosive cash flow growth this decade.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Stock Market Crash Is Coming: 5 High-Conviction Stocks to Buy Hand Over Fist When It Happens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Stock Market Crash Is Coming: 5 High-Conviction Stocks to Buy Hand Over Fist When It Happens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-20 09:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/19/stock-market-crash-coming-5-high-conviction-stocks/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It might be the last thing you want to hear, but it's the truth:A stock market crash is inevitable.\nSince the March 23, 2020 bottom, investors have enjoyed a historically strong bounce-back rally -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/19/stock-market-crash-coming-5-high-conviction-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRWD":"CrowdStrike Holdings, Inc.","AMZN":"亚马逊","V":"Visa","NEP":"Nextera Energy Partners"},"source_url":"https://www.fool.com/investing/2021/06/19/stock-market-crash-coming-5-high-conviction-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126454279","content_text":"It might be the last thing you want to hear, but it's the truth:A stock market crash is inevitable.\nSince the March 23, 2020 bottom, investors have enjoyed a historically strong bounce-back rally -- the widely followedS&P 500(SNPINDEX:^GSPC)has gained an impressive 90%. But both history and valuation metrics unequivocally suggest that a big drop is upcoming for the stock market.\nHistory is pretty clear that trouble lies ahead\nFor example, there have beenone or two double-digit percentage declineswithin the three years following a bottom in each of the previous eight bear markets prior to the coronavirus crash (i.e., dating back to 1960). Although bull markets tend to last years, rebounds from a bear market are never this smooth. We're nearly 15 months past the March 2020 bear-market bottom in the S&P 500 and have yet to see anything close to a double-digit correction.\nTo add to this point, data from market analytics firm Yardeni Research shows that there have been 38 double-digit declines in the S&P 500 over the past 71 years. That's a crash or correction, on average,every 1.87 years. Though the market doesn't adhere to averages, it does give a general sense of when to expect these hiccups.\nOn a valuation basis, the S&P 500's Shiller price-to-earnings (P/E) ratio is a waving red flag. The S&P 500's Shiller P/E -- a measure of inflation-adjusted earnings over the previous 10 years -- almost hit 38 earlier this week. That more than doubles its 151-year average, and it's the highest level in nearly two decades. The previous four times the Shiller P/E surpassed and held above 30 during a bull market rally, the indexsubsequently declined by a minimum of 20%.\nMake no mistake about it -- a stock market crash is coming.\nEvery crash or correction is an opportunity for patient investors to make money\nHowever, a crash is no reason to duck and cover. While history may signal trouble ahead, it also tells us that each and every double-digit decline has been a buying opportunity. Eventually, every big drop in the major indexes is erased by a bull-market rally. When the next crash does occur, the following five high-conviction stocks can be confidently bought hand over fist.\nCrowdStrike Holdings\nCybersecurity is projected to beone of the safest double-digit growth trendsthis decade. No matter the size of the business or the state of the U.S./global economy, protecting enterprise and consumer data is paramount. This means cloud-based cybersecurity stockCrowdStrike Holdings(NASDAQ:CRWD)can thrive in any environment.\nCrowdStrike's successderives from its cloud-native Falcon security platform. Because it's built in the cloud and relies on artificial intelligence, it's growing smarter at identifying and responding to threats all the time. It's currently overseeing 6 trillion events on a weekly basis, and it's far more cost-effective at protecting data than on-premise solutions.\nWe can also look to the company's income statements to see clear-cut evidence that businesses favor CrowdStrike's cybersecurity platform. It's been retaining 98% of its clients, has seen existing clients spend 23% to 47% more on a year-over-year basis for the past 12 quarters, and recently reported that 64% of its customers have purchased at least four cloud module subscriptions. Scaling with its customers is CrowdStrike's ticket to big-time cash flow expansion.\nFacebook\nBrand-name businesses can make patient investors a fortune, and social media giantFacebook(NASDAQ:FB)is the perfect example.\nWhen the curtain closed on March, Facebook tallied 2.85 billion monthly active users (MAU) visiting its namesake site and an additional 600 million unique MAUs visiting WhatsApp or Instagram, which it also owns. All told, this equates to44% of the global populationinteracting with its owned sites each month. There's simply no social media platform businesses can go to get their message to a broader (or potentially targeted) audience, which is why Facebook ad-pricing power is so strong.\nBut here's the kicker: Facebookhasn't even put the pedal to the metal. Although it's on track to generate more than $100 billion in advertising revenue in 2021, nearly all of these ad sales are coming from its namesake site and Instagram. WhatsApp and Facebook Messenger, which are two of the six most-visited social sites in the world, aren't being meaningfully monetized as of yet. Further, the company's Oculus virtual reality devices are still in the early stage of their growth. Suffice it to say, Facebook offers ample upside as its other operating segments are monetized and mature.\nNextEra Energy\nAnother high-conviction stock to buy hand over fist the next time a crash or steep correction strikes is electric utility stockNextEra Energy(NYSE:NEE).\nDid I put you to sleep when I said \"electric utility stock?\" Electric utilities are traditionally known for their market-topping dividend yields and persistently low growth rates. But this doesn't describe NextEra Energy. NextEra has aggressively invested in renewable energy projects and is leading the country in solar and wind capacity. As a result of these investments, its electric generation costs have declined and its compound annual growth ratehas consistently been in the high single digitsfor more than a decade. It also doesn't hurt that NextEra is front-running any potential green-energy legislation that might come out of Washington.\nIn addition to growth rates that are well above the sector average, NextEra still benefits from the predictability of energy demand. For instance, its regulated utilities (i.e., those not powered by renewable energy) require approval from state utility commissions before price hikes can be passed along to households. This might sound like an inconvenience, but it's actually great news. It means NextEra won't be exposed to potentially volatile wholesale pricing.\nVisa\nWhen the next stock market crash arrives, payment processing kingpinVisa(NYSE:V)is a winning company to confidently buy hand over fist. It's also another brand-name company thatcan still make its shareholders a fortune.\nBuying into the Visa growth story is a simple numbers game. Visa grows its revenue and profits when consumers and businesses are spending more. This happens when the U.S. and global economy are expanding. Although contractions and recessions are an inevitable part of the economic cycle, they tend to be short-lived. Meanwhile, periods of economic expansion are almost always measured in years. Buying into Visa during these short-lived crashes or corrections should allow long-term investors to be handsomely rewarded by this numbers game.\nThe other interesting thing about Visa is thatit's shunned becoming a lender. You'd think that Visa could generate big bucks from interest income and fees by lending during these long-lived periods of expansion. But lending would also expose Visa to the credit delinquencies that arise during recessions. Operating solely as a payment processor means not having to set aside cash to cover delinquencies. It's why Visa rebounds so much faster than most financial stocks following a recession.\nAmazon\nLastly (andwho couldn't see this coming?), investors should take any discount they can get during a crash on e-commerce behemothAmazon(NASDAQ:AMZN).\nAmazon's online marketplace has proved virtually unstoppable for well over a decade. An April 2021 report from eMarketer pegged the company's share of U.S. online sales at 40.4%. That more than quintuples its next-closest competitor and effectively solidifies Amazon as the go-to source for online shopping in the U.S.\nWhat about those pesky low retail margins, you ask? Amazon has signed up more than 200 million people globally to a Prime membership. The fees collected from Prime members help to offset some of the company's retail-based margin weakness. Prime members are extremely loyal to the Amazon ecosystem and spend far more than non-members, too.\nBut it's Amazon's cloud infrastructure segmentthat's the superstar. Amazon Web Services (AWS) brings in around one-eighth of the company's total sales but accounts for well over half its operating income. Since cloud margins are superior to retail and advertising margins, AWS is the company's key to explosive cash flow growth this decade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160820480,"gmtCreate":1623781883840,"gmtModify":1703819327820,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Will go up","listText":"Will go up","text":"Will go up","images":[{"img":"https://static.tigerbbs.com/ac1f3cbc64784721bc559af8370a2500","width":"1080","height":"2382"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160820480","isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":117025881,"gmtCreate":1623110988243,"gmtModify":1704196164665,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Target","listText":"Target","text":"Target","images":[{"img":"https://static.tigerbbs.com/a71bdc3962ba2373d3867d49c13f315b","width":"1080","height":"3333"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117025881","isVote":1,"tweetType":1,"viewCount":240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":112692170,"gmtCreate":1622864571090,"gmtModify":1704192688646,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/112692170","repostId":"2140401760","repostType":2,"repost":{"id":"2140401760","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1622819067,"share":"https://ttm.financial/m/news/2140401760?lang=&edition=fundamental","pubTime":"2021-06-04 23:04","market":"us","language":"en","title":"Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2140401760","media":"T-Reuters","summary":"Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Tre","content":"<html><body><p>Gilead Sciences Inc <gild.o>:Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - Trodelvy Improved Progression-Free Survival (Pfs), With A 59% Reduction In The Risk Of Disease Worsening Or Death.Gilead Sciences - Additional Results Showed Trodelvy Demonstrated A Higher Overall Response Rate Compared With Chemotherapy.Gilead Sciences - Safety Profile Of Trodelvy In Subgroup Was Consistent With Prior Reports.Further Company Coverage: Gild.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</gild.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrodelvy Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-06-04 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Gilead Sciences Inc <gild.o>:Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - Trodelvy Improved Progression-Free Survival (Pfs), With A 59% Reduction In The Risk Of Disease Worsening Or Death.Gilead Sciences - Additional Results Showed Trodelvy Demonstrated A Higher Overall Response Rate Compared With Chemotherapy.Gilead Sciences - Safety Profile Of Trodelvy In Subgroup Was Consistent With Prior Reports.Further Company Coverage: Gild.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</gild.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","SUP":"Superior Industries International","SMP":"Standard Motor Products Inc","SPN":"Superior Energy Services Inc"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140401760","content_text":"Gilead Sciences Inc :Trodelvy® Demonstrates Superior Outcomes To Standard Of Care In Second-Line Treatment Of Metastatic Triple-Negative Breast Cancer In Phase 3 Ascent Study.Gilead Sciences - Trodelvy Improved Progression-Free Survival (Pfs), With A 59% Reduction In The Risk Of Disease Worsening Or Death.Gilead Sciences - Additional Results Showed Trodelvy Demonstrated A Higher Overall Response Rate Compared With Chemotherapy.Gilead Sciences - Safety Profile Of Trodelvy In Subgroup Was Consistent With Prior Reports.Further Company Coverage: Gild.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":118485409,"gmtCreate":1622753156701,"gmtModify":1704190404494,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>good bet","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>good bet","text":"$Sundial Growers Inc.(SNDL)$good bet","images":[{"img":"https://static.tigerbbs.com/d8dbedf3451af65ccd8f4067f7511141","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/118485409","isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":118154424,"gmtCreate":1622725314668,"gmtModify":1704189793572,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/118154424","repostId":"1140207862","repostType":4,"repost":{"id":"1140207862","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1622722823,"share":"https://ttm.financial/m/news/1140207862?lang=&edition=fundamental","pubTime":"2021-06-03 20:20","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1140207862","media":"Tiger Newspress","summary":"Nasdaq futures lead stock dropMeme stocks fluctuated greatlyU.S. equity futures dropped with Europea","content":"<ul><li>Nasdaq futures lead stock drop</li></ul><ul><li>Meme&nbsp;stocks fluctuated greatly</li></ul><p>U.S. equity futures dropped with European stocks on Thursday as fresh geopolitical tensions added to investor concerns over inflation and a potential reduction in stimulus.World stocks stepped back from record highs on Thursday as investors weighed inflation concerns ahead of key U.S. economic data, while oil prices rose for a third straight session.</p><p>At 8:12 a.m. ET, Dow e-minis were down 233 points, or 0.67%, S&amp;P 500 e-minis were down 33 points, or 0.78%, and Nasdaq 100 e-minis were down 149.25 points, or 1.09%.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5551aa2c67b20860026ceb7c9155636\" tg-width=\"1080\" tg-height=\"405\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:12</span></p><p>A weekly U.S. unemployment report and May private payrolls data on Thursday will be followed by the monthly jobs numbers on Friday. Investors will be looking for signs of an economic rebound and rising inflation.</p><p>Initial jobless claims fell below 400,000 for the first time since the early days of the Covid-19 pandemic as the labor market continues to recover, the Labor Department reported Thursday.</p><p>Initial claims fell to 385,000 for the week ended May 29, a decline from the previous week's 405,000 and below the Dow Jones estimate of 393,000.</p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><b>AMC Entertainment&nbsp;(AMC) </b>– AMC&nbsp;filed to sell up to 11.55 million common shares&nbsp;“from time to time,” according to a Securities and Exchange Commission filing, but cautioned against investing in the stock due to recent moves “unrelated to our underlying business.” AMC&nbsp;had initially surged in the premarket&nbsp;after nearly doubling Wednesday, but fell 9.7% after the filing.</p><p><b>BlackBerry&nbsp;(BB),Koss&nbsp;(KOSS),GameStop&nbsp;(GME),Bed Bath &amp; Beyond&nbsp;(BBBY)</b> – These stocks remain on watch today, after surging yesterday on investor enthusiasm for the so-called “meme” stocks. BlackBerry jumped 11.2% in the premarket, but Koss fell 10.1%, GameStop lost 2.3% and Bed Bath &amp; Beyond dropped 12.9% after soaring 62% Wednesday.</p><p><b>Express&nbsp;(EXPR) </b>– The apparel retailer reported a quarterly loss of 55 cents per share, smaller than the 58 cents a share that analysts were expecting. Revenue topped Street forecasts and Express said it expects sequential comparable sales improvement throughout this year. Its shares fell 7.1% in the premarket after an initial jump higher.</p><p><b>Meredith Corp.&nbsp;(MDP) </b>– Meredith accepted a revised bid from&nbsp;Gray Television(GTN) for its local media group. Meredith shareholders will now receive $16.99 per share in cash, up from the prior $14.51 a share, plus one share in the new post-close version of Meredith.</p><p><b>Ciena&nbsp;(CIEN) </b>– The networking equipment and services company reported quarterly earnings of 62 cents per share, 14 cents a share above estimates. Revenue also came in above analysts’ projections. Ciena said it was helped by an improving market environment and a rebound in customer spending. Ciena gained 1.1% in premarket trading.</p><p><b>J.M. Smucker&nbsp;(SJM)</b> – The food producer beat estimates by 22 cents a share, with quarterly profit of $1.89 per share. Revenue came in slightly above forecasts. Sales fell compared with a year earlier, however, when homebound consumers stocked up as the pandemic took hold. Smucker did issue an upbeat full-year earnings forecast.</p><p><b>PVH&nbsp;(PVH)</b> – PVH earned $1.92 per share for its latest quarter, more than double the consensus estimate of 83 cents a share. The company behind apparel brands like Tommy Hilfiger and Calvin Klein also saw revenue beat estimates, and it also raised its full-year forecast.</p><p><b>Exxon Mobil&nbsp;(XOM)</b> – Exxon said in an SEC filing that hedge fund Engine No. 1&nbsp;had won a third seat on the energy giant’s board. Engine No. 1 – a small investor in Exxon – won a surprise victory with a campaign centered on environmental concerns.</p><p><b>FireEye&nbsp;(FEYE) </b>– FireEye&nbsp;announced the sale&nbsp;of its security software products unit – along with the FireEye name – to private-equity firm Symphony Technology for $1.2 billion. The business that remains will be called Mandiant Solutions, the same name used by CEO Kevin Mandia’s business before its sale to FireEye in 2014. FireEye shares tumbled 7.5% in the premarket.</p><p><b>Emergent BioSolutions&nbsp;(EBS)</b> – The Food and Drug Administration is working with&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;AstraZeneca&nbsp;(AZN) to ensure that Covid-19 vaccine doses produced at an Emergent plant in Baltimore are uncontaminated and safe to use. That comes after the plant accidentally contaminated doses of J&amp;J’s vaccine with the active ingredient in AstraZeneca’s treatment.</p><p><b>Splunk&nbsp;(SPLK)</b> – Splunk reported a greater-than-expected loss for the first quarter, though the maker of network analytics software did see revenue beat Wall Street forecasts. Splunk has been transitioning customers to cloud-based versions of its software, and recurring cloud revenue did jump 83% during the quarter compared to a year ago. Splunk lost 5.1% in premarket trading.</p><p><b>Tilray&nbsp;(TLRY)</b> – The cannabis producer’s shares rallied 3.6% in premarket trading after Cantor Fitzgerald rolled out new estimates after the completion of Tilray’s merger with Aphria and rated the stock “overweight.” Cantor cites the combined company’s scale as well as upbeat overseas prospects.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-03 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul><li>Nasdaq futures lead stock drop</li></ul><ul><li>Meme&nbsp;stocks fluctuated greatly</li></ul><p>U.S. equity futures dropped with European stocks on Thursday as fresh geopolitical tensions added to investor concerns over inflation and a potential reduction in stimulus.World stocks stepped back from record highs on Thursday as investors weighed inflation concerns ahead of key U.S. economic data, while oil prices rose for a third straight session.</p><p>At 8:12 a.m. ET, Dow e-minis were down 233 points, or 0.67%, S&amp;P 500 e-minis were down 33 points, or 0.78%, and Nasdaq 100 e-minis were down 149.25 points, or 1.09%.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5551aa2c67b20860026ceb7c9155636\" tg-width=\"1080\" tg-height=\"405\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:12</span></p><p>A weekly U.S. unemployment report and May private payrolls data on Thursday will be followed by the monthly jobs numbers on Friday. Investors will be looking for signs of an economic rebound and rising inflation.</p><p>Initial jobless claims fell below 400,000 for the first time since the early days of the Covid-19 pandemic as the labor market continues to recover, the Labor Department reported Thursday.</p><p>Initial claims fell to 385,000 for the week ended May 29, a decline from the previous week's 405,000 and below the Dow Jones estimate of 393,000.</p><p><b>Stocks making the biggest moves in the premarket:</b></p><p><b>AMC Entertainment&nbsp;(AMC) </b>– AMC&nbsp;filed to sell up to 11.55 million common shares&nbsp;“from time to time,” according to a Securities and Exchange Commission filing, but cautioned against investing in the stock due to recent moves “unrelated to our underlying business.” AMC&nbsp;had initially surged in the premarket&nbsp;after nearly doubling Wednesday, but fell 9.7% after the filing.</p><p><b>BlackBerry&nbsp;(BB),Koss&nbsp;(KOSS),GameStop&nbsp;(GME),Bed Bath &amp; Beyond&nbsp;(BBBY)</b> – These stocks remain on watch today, after surging yesterday on investor enthusiasm for the so-called “meme” stocks. BlackBerry jumped 11.2% in the premarket, but Koss fell 10.1%, GameStop lost 2.3% and Bed Bath &amp; Beyond dropped 12.9% after soaring 62% Wednesday.</p><p><b>Express&nbsp;(EXPR) </b>– The apparel retailer reported a quarterly loss of 55 cents per share, smaller than the 58 cents a share that analysts were expecting. Revenue topped Street forecasts and Express said it expects sequential comparable sales improvement throughout this year. Its shares fell 7.1% in the premarket after an initial jump higher.</p><p><b>Meredith Corp.&nbsp;(MDP) </b>– Meredith accepted a revised bid from&nbsp;Gray Television(GTN) for its local media group. Meredith shareholders will now receive $16.99 per share in cash, up from the prior $14.51 a share, plus one share in the new post-close version of Meredith.</p><p><b>Ciena&nbsp;(CIEN) </b>– The networking equipment and services company reported quarterly earnings of 62 cents per share, 14 cents a share above estimates. Revenue also came in above analysts’ projections. Ciena said it was helped by an improving market environment and a rebound in customer spending. Ciena gained 1.1% in premarket trading.</p><p><b>J.M. Smucker&nbsp;(SJM)</b> – The food producer beat estimates by 22 cents a share, with quarterly profit of $1.89 per share. Revenue came in slightly above forecasts. Sales fell compared with a year earlier, however, when homebound consumers stocked up as the pandemic took hold. Smucker did issue an upbeat full-year earnings forecast.</p><p><b>PVH&nbsp;(PVH)</b> – PVH earned $1.92 per share for its latest quarter, more than double the consensus estimate of 83 cents a share. The company behind apparel brands like Tommy Hilfiger and Calvin Klein also saw revenue beat estimates, and it also raised its full-year forecast.</p><p><b>Exxon Mobil&nbsp;(XOM)</b> – Exxon said in an SEC filing that hedge fund Engine No. 1&nbsp;had won a third seat on the energy giant’s board. Engine No. 1 – a small investor in Exxon – won a surprise victory with a campaign centered on environmental concerns.</p><p><b>FireEye&nbsp;(FEYE) </b>– FireEye&nbsp;announced the sale&nbsp;of its security software products unit – along with the FireEye name – to private-equity firm Symphony Technology for $1.2 billion. The business that remains will be called Mandiant Solutions, the same name used by CEO Kevin Mandia’s business before its sale to FireEye in 2014. FireEye shares tumbled 7.5% in the premarket.</p><p><b>Emergent BioSolutions&nbsp;(EBS)</b> – The Food and Drug Administration is working with&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;AstraZeneca&nbsp;(AZN) to ensure that Covid-19 vaccine doses produced at an Emergent plant in Baltimore are uncontaminated and safe to use. That comes after the plant accidentally contaminated doses of J&amp;J’s vaccine with the active ingredient in AstraZeneca’s treatment.</p><p><b>Splunk&nbsp;(SPLK)</b> – Splunk reported a greater-than-expected loss for the first quarter, though the maker of network analytics software did see revenue beat Wall Street forecasts. Splunk has been transitioning customers to cloud-based versions of its software, and recurring cloud revenue did jump 83% during the quarter compared to a year ago. Splunk lost 5.1% in premarket trading.</p><p><b>Tilray&nbsp;(TLRY)</b> – The cannabis producer’s shares rallied 3.6% in premarket trading after Cantor Fitzgerald rolled out new estimates after the completion of Tilray’s merger with Aphria and rated the stock “overweight.” Cantor cites the combined company’s scale as well as upbeat overseas prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓",".SPX":"S&P 500 Index","GME":"游戏驿站","BBBY":"3B家居",".IXIC":"NASDAQ Composite","AMC":"AMC院线",".DJI":"道琼斯","KOSS":"高斯电子","EXPR":"Express, Inc.","TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140207862","content_text":"Nasdaq futures lead stock dropMeme stocks fluctuated greatlyU.S. equity futures dropped with European stocks on Thursday as fresh geopolitical tensions added to investor concerns over inflation and a potential reduction in stimulus.World stocks stepped back from record highs on Thursday as investors weighed inflation concerns ahead of key U.S. economic data, while oil prices rose for a third straight session.At 8:12 a.m. ET, Dow e-minis were down 233 points, or 0.67%, S&P 500 e-minis were down 33 points, or 0.78%, and Nasdaq 100 e-minis were down 149.25 points, or 1.09%.*Source From Tiger Trade, EST 08:12A weekly U.S. unemployment report and May private payrolls data on Thursday will be followed by the monthly jobs numbers on Friday. Investors will be looking for signs of an economic rebound and rising inflation.Initial jobless claims fell below 400,000 for the first time since the early days of the Covid-19 pandemic as the labor market continues to recover, the Labor Department reported Thursday.Initial claims fell to 385,000 for the week ended May 29, a decline from the previous week's 405,000 and below the Dow Jones estimate of 393,000.Stocks making the biggest moves in the premarket:AMC Entertainment (AMC) – AMC filed to sell up to 11.55 million common shares “from time to time,” according to a Securities and Exchange Commission filing, but cautioned against investing in the stock due to recent moves “unrelated to our underlying business.” AMC had initially surged in the premarket after nearly doubling Wednesday, but fell 9.7% after the filing.BlackBerry (BB),Koss (KOSS),GameStop (GME),Bed Bath & Beyond (BBBY) – These stocks remain on watch today, after surging yesterday on investor enthusiasm for the so-called “meme” stocks. BlackBerry jumped 11.2% in the premarket, but Koss fell 10.1%, GameStop lost 2.3% and Bed Bath & Beyond dropped 12.9% after soaring 62% Wednesday.Express (EXPR) – The apparel retailer reported a quarterly loss of 55 cents per share, smaller than the 58 cents a share that analysts were expecting. Revenue topped Street forecasts and Express said it expects sequential comparable sales improvement throughout this year. Its shares fell 7.1% in the premarket after an initial jump higher.Meredith Corp. (MDP) – Meredith accepted a revised bid from Gray Television(GTN) for its local media group. Meredith shareholders will now receive $16.99 per share in cash, up from the prior $14.51 a share, plus one share in the new post-close version of Meredith.Ciena (CIEN) – The networking equipment and services company reported quarterly earnings of 62 cents per share, 14 cents a share above estimates. Revenue also came in above analysts’ projections. Ciena said it was helped by an improving market environment and a rebound in customer spending. Ciena gained 1.1% in premarket trading.J.M. Smucker (SJM) – The food producer beat estimates by 22 cents a share, with quarterly profit of $1.89 per share. Revenue came in slightly above forecasts. Sales fell compared with a year earlier, however, when homebound consumers stocked up as the pandemic took hold. Smucker did issue an upbeat full-year earnings forecast.PVH (PVH) – PVH earned $1.92 per share for its latest quarter, more than double the consensus estimate of 83 cents a share. The company behind apparel brands like Tommy Hilfiger and Calvin Klein also saw revenue beat estimates, and it also raised its full-year forecast.Exxon Mobil (XOM) – Exxon said in an SEC filing that hedge fund Engine No. 1 had won a third seat on the energy giant’s board. Engine No. 1 – a small investor in Exxon – won a surprise victory with a campaign centered on environmental concerns.FireEye (FEYE) – FireEye announced the sale of its security software products unit – along with the FireEye name – to private-equity firm Symphony Technology for $1.2 billion. The business that remains will be called Mandiant Solutions, the same name used by CEO Kevin Mandia’s business before its sale to FireEye in 2014. FireEye shares tumbled 7.5% in the premarket.Emergent BioSolutions (EBS) – The Food and Drug Administration is working with Johnson & Johnson (JNJ) and AstraZeneca (AZN) to ensure that Covid-19 vaccine doses produced at an Emergent plant in Baltimore are uncontaminated and safe to use. That comes after the plant accidentally contaminated doses of J&J’s vaccine with the active ingredient in AstraZeneca’s treatment.Splunk (SPLK) – Splunk reported a greater-than-expected loss for the first quarter, though the maker of network analytics software did see revenue beat Wall Street forecasts. Splunk has been transitioning customers to cloud-based versions of its software, and recurring cloud revenue did jump 83% during the quarter compared to a year ago. Splunk lost 5.1% in premarket trading.Tilray (TLRY) – The cannabis producer’s shares rallied 3.6% in premarket trading after Cantor Fitzgerald rolled out new estimates after the completion of Tilray’s merger with Aphria and rated the stock “overweight.” Cantor cites the combined company’s scale as well as upbeat overseas prospects.","news_type":1},"isVote":1,"tweetType":1,"viewCount":124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":119229433,"gmtCreate":1622550650622,"gmtModify":1704186108659,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119229433","repostId":"2138791127","repostType":2,"repost":{"id":"2138791127","kind":"news","pubTimestamp":1622118600,"share":"https://ttm.financial/m/news/2138791127?lang=&edition=fundamental","pubTime":"2021-05-27 20:30","market":"us","language":"en","title":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents","url":"https://stock-news.laohu8.com/highlight/detail?id=2138791127","media":"GlobeNewswire","summary":"Leverages TURBO-ZM™ Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulat","content":"<html><body><p><em>Leverages TURBO-ZM™</em><em> Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs)</em><br/></p>\n<p><em>Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment</em><em> of Cystic Fibrosis</em></p>\n<p>WALTHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/ELOX\">Eloxx Pharmaceuticals, Inc.</a> (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis (CF) patients with nonsense mutations.</p>\n<p>“We are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables critical research to advance and further evaluate the potential of the TURBO-ZM™ synthetic chemistry platform to develop a new class of therapies. We have tremendous confidence in the potential of RMAs designed with TURBO-ZM™ to treat rare genetic diseases,” said Sumit Aggarwal, President and Chief Executive Officer. “In preclinical models, novel RMAs have demonstrated the potential for significant readthrough and functional activity.”</p>\n<p>Mr. Aggarwal continued, “In addition, the development of a Ribosome Modulating Agent for the treatment of CF with support from the Cystic Fibrosis Foundation complements our ongoing ELX-02 program, currently in Phase 2 clinical trials. Data from these Phase 2 trials is expected in the second half of this year.”</p>\n<p><strong>About Eloxx Pharmaceuticals</strong></p>\n<p>Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.</p>\n<p>For more information, please visit www.eloxxpharma.com.</p>\n<p><strong>Forward-looking Statements</strong></p>\n<p><em>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding the expected timing of trials and results from clinical studies of our product candidate, the expansion of our clinical trial sites and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. </em></p>\n<p><em>Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks,uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at </em><em>www.sec.gov</em><em> and the “Financials &amp; Filings” page of our website at </em><em>https://investors.eloxxpharma.com/financial-information/sec-filings</em></p>\n<p><em>All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. </em></p>\n<p><strong>Contact</strong></p>\n<p>Investors<br/>John Woolford<br/>john.woolford@westwicke.com<br/>443.213.0506</p>\n<p>Media<br/>Laureen Cassidy<br/>laureen@outcomescg.com</p>\n<p>SOURCE: Eloxx Pharmaceuticals, Inc.</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/e7c6cb58-f14c-46f8-8695-2595c6937f03\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-27 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/eloxx-pharmaceuticals-announces-funding-award-123000023.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Leverages TURBO-ZM™ Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs)\nComplements ELX-02 program in Phase 2 Clinical Trials for the Treatment of Cystic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/eloxx-pharmaceuticals-announces-funding-award-123000023.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/_dEWTIIg7QkSnw5sHBHH_w--~B/aD0xODAwO3c9MjEwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/uu/api/res/1.2/kjX_a_h.bhQd.eOM7lsFxA--~B/aD0xODAwO3c9MjEwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/bcfc5fd94f5c621327303f3cfdec45a3","relate_stocks":{"ELOX":"Eloxx制药"},"source_url":"https://finance.yahoo.com/news/eloxx-pharmaceuticals-announces-funding-award-123000023.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2138791127","content_text":"Leverages TURBO-ZM™ Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs)\nComplements ELX-02 program in Phase 2 Clinical Trials for the Treatment of Cystic Fibrosis\nWALTHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis (CF) patients with nonsense mutations.\n“We are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables critical research to advance and further evaluate the potential of the TURBO-ZM™ synthetic chemistry platform to develop a new class of therapies. We have tremendous confidence in the potential of RMAs designed with TURBO-ZM™ to treat rare genetic diseases,” said Sumit Aggarwal, President and Chief Executive Officer. “In preclinical models, novel RMAs have demonstrated the potential for significant readthrough and functional activity.”\nMr. Aggarwal continued, “In addition, the development of a Ribosome Modulating Agent for the treatment of CF with support from the Cystic Fibrosis Foundation complements our ongoing ELX-02 program, currently in Phase 2 clinical trials. Data from these Phase 2 trials is expected in the second half of this year.”\nAbout Eloxx Pharmaceuticals\nEloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.\nFor more information, please visit www.eloxxpharma.com.\nForward-looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding the expected timing of trials and results from clinical studies of our product candidate, the expansion of our clinical trial sites and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words. \nForward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks,uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings” page of our website at https://investors.eloxxpharma.com/financial-information/sec-filings\nAll forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. \nContact\nInvestorsJohn Woolfordjohn.woolford@westwicke.com443.213.0506\nMediaLaureen Cassidylaureen@outcomescg.com\nSOURCE: Eloxx Pharmaceuticals, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":251,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":134968540,"gmtCreate":1622201393480,"gmtModify":1704181361974,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Eyeing","listText":"Eyeing","text":"Eyeing","images":[{"img":"https://static.tigerbbs.com/37cf493a3287afb161ecb97f816926bb","width":"1080","height":"3223"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/134968540","isVote":1,"tweetType":1,"viewCount":186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":193360071,"gmtCreate":1620766385493,"gmtModify":1704347937953,"author":{"id":"3559365521897414","authorId":"3559365521897414","name":"AHEAD","avatar":"https://static.tigerbbs.com/dd5ec3cc2c503d9bbb111d93e7d1ab9b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3559365521897414","idStr":"3559365521897414"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193360071","isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}